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Objectives To determine the degree of bacterial susceptibility to the most commonly used drugs for
respiratory infections in Norway, and to find if bacterial resistance is emerging.
Methods Clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and group A streptococci from
respiratory tract specimens and from the eye were collected from different parts of Norway during two study
periods. During the first period (1993–1994), three laboratories, covering 15% of the Norwegian
population, participated. During the second study period in 1997, five laboratories, covering 27% of the
population, collected respiratory isolates. In total, 494 isolates of S. pneumoniae, 696 isolates of H. influenzae
and 694 isolates of group A streptococci were included in the study. The study population comprised
children and adults attending hospital and general practice. Bacterial susceptibility was determined by the E
test, and breakpoints were according to the National Committee for Clinical Laboratory Standards
(NCCLS).
Results The prevalence of bacterial resistance was low, and we observed no significant increase in bacterial
resistance between the two study periods. In 1997, only 0.6% of pneumococci had decreased susceptibility to
penicillin, 1.6% of group A streptococci were resistant to erythromycin, and 6.7% of all isolates of H.
influenzae produced b-lactamase.
Conclusions The prevalence of antibiotic resistance in respiratory pathogens in Norway is low.
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INTRODUCTION
During recent years, bacterial resistance has become a major
health problem in many countries. Bacterial resistance in
respiratory pathogens such as Haemophilus influenzae, Streptococ-
cus pneumoniae and Streptococcus pyogenes is particularly impor-
tant. Infections with these pathogens are common in all age
groups, and their contribution to the total consumption of
antibacterial agents in a population is therefore significant.
Despite the many infectious disease control and surveillance
programs, the medical community has not been able to stop the
global spread of resistant bacteria. Penicillin-resistant S. pneu-
mococci strains are spreading in many parts of the world [1–6],
causing up to 40–60% of all pneumococcal infections in
some European countries. In the USA, the percentage of
H. influenzae producing b-lactamase increased from 20% in
1986 [7] to 36.4% in 1995 [8]. In Europe, 50–60% of type b
isolates of H. influenzae from children in Spain produced
b-lactamase [9]. In developing countries, the degree of resis-
tance is not uniform; in Egypt, all blood culture isolates of H.
influenzae and 93% of nasopharyngeal isolates were susceptible
to ampicillin [10], whereas in India, 29% of isolates of H.
influenzae produced b-lactamase [11]. It has been demonstrated
[12] that a high proportion of both respiratory and systemic
isolates of group A streptococci may become resistant to
erythromycin following an increase in consumption of this
drug in a given population.
Increased bacterial resistance is associated with high anti-
biotic consumption [2,13–15]. In Norway, consumption of
antibacterial agents is low, but little is known of bacterial
susceptibility. It has also been found that penicillin-resistant
pneumococci that were imported from Spain to Iceland may
establish and spread because of high consumption of antibac-
terials [14]. A large number of Norwegians travel to southern
Europe every year, and may return with resistant bacteria. The
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present study was performed to assess the antibiotic resistance
problem in Norway. Because respiratory diseases are common
and significantly contribute to the total consumption of anti-
bacterials, we decided to collect clinical isolates of respiratory
pathogens to determine their susceptibility to the most com-
monly used antibacterials for respiratory diseases in Norway.
MATERIALS AND METHODS
Collection of bacterial isolates
The material is shown in Table 1. All consecutive clinical
isolates of H. influenzae, S. pneumoniae and S. pyogenes (group
A streptococci) from the respiratory tract and from the eye were
collected during two study periods. In study period I, S.
pneumoniae isolates were collected during a 3-month period
(January to March 1994) in two laboratories in northern Nor-
way (Tromsø and Bodø) and one in southern Norway (Skien).
These laboratories covered four of 20 Counties in Norway
(Telemark, Nordland, Troms and Finnmark) and 15.3% of the
Norwegian population (630 000 of 4.45 million). H. influenzae
and S. pyogenes were collected in two of these laboratories
(Tromsø and Skien, covering 8.7% of the population); H.
influenzae during the period from January to March 1994,
and S. pyogenes in December 1993. In total, 518 respiratory
isolates were included in the study (Table 1), of which 176 were
pneumococci, 161 were H. influenzae and 181 were group A
streptococci. S. pneumoniae was predominantly isolated from the
eye (44.9%) and the nasopharynx (28.4%), S. pyogenes from the
throat (77.9%), and H. influenzae from the nasopharynx (38.5%)
and the eye (37.9%). In study period II, all consecutive clinical
isolates collected in the months February and October 1997
from five laboratories covering six counties (in addition to the
above mentioned, also Østfold and Rogaland in southern
Norway) or 27.9% of the Norwegian population (1.24 million),
were included in the study. In total, 461 isolates of H. influenzae,
318 of S. pneumoniae and 513 of S. pyogenes were included in the
study (Table 1). S. pneumoniae was most frequently isolated from
the nasopharynx (37.7%) and the eye (27.7%), S. pyogenes from
the throat (81.7%), and H. influenzae from the eye (30.8%) and
the nasopharynx (26.7%). Initially, the bacteria were isolated
and identified at the local laboratory according to its own
procedure. All isolates were kept frozen at 708C before being
sent to the Department of Medical Microbiology at the
Nordland Central Hospital in Bodø, where the identification
and susceptibility tests were performed.
Identification of bacteria
Pneumococci were identified on the basis of typical colony
morphology on blood agar, susceptibility to optochin, and a
commercially available agglutination test (Slidex, BioMerieux,
Marcy-l’Etoile, France). H. influenzae was identified by its
dependence on X and V factors for growth on tryptic soy
medium, and was typed using antisera against serotypes a–f
(Murex Diagnostics Ltd., Chatillon, France). Group A strep-
tococci were identified by typical colony morphology with
b-hemolysis on sheep blood agar, susceptibility to bacitracin,
and agglutination using the Strepslide II system (Porton,
Cambridge, MA, USA).
Susceptibility testing
All MIC determinations were performed with the E test
(Biodisk AB, Solna, Sweden). For group A streptococci and
pneumococci, the E test was done on Mueller–Hinton agar
with 5% sheep blood. For H. influenzae, haemophilus test
medium (HTM) medium was used. Bacterial suspensions were
made from overnight cultures and were spectrophotometrically
adjusted to approximately 1 107 bacteria/mL. We tested the
bacteria for susceptibility to those antibiotics which are most
commonly used for oral treatment of upper respiratory infec-
tions in Norway. All bacteria were tested for susceptibility to
erythromycin, doxycycline and cephalothin. Group A strepto-
cocci and pneumococci were tested for susceptibility to peni-
cillin G, whereas H. influenzae was tested for susceptibility to
ampicillin. The E test was performed according to the man-
ufacturer’s recommendations, with quality controls being
Table1 Material: number of isolates from different Counties
H. influenzae S. pneumoniae S. pyogenes
County (no. of inhabitants in1000) 1993^1994 1997 1993^1994 1997 1993^1994 1997
Telemark (165) 81 74 70 44 79 96
Troms and Finnmark (230) 80 74 63 50 102 53
Nordland (240) 0 65 43 28 0 80
Rogaland (360) 0 183 0 136 0 185
$stfold (240) 0 65 0 60 0 99
Total (1235) 161 461 176 318 181 513
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reference strains for streptococci (S. pneumoniae ATCC 49619)
and H. influenzae (ATCC 10211). Two milliliters of the bacter-
ial suspension was added to the plate and later removed when all
the surface had been wetted. The plates were dried for 30 min
before the E test strips were added. The plates were subse-
quently incubated for 18–24 h in a 5% CO2 atmosphere. H.
influenzae was also tested for production of b-lactamase, using
the clover-leaf test.
The antibacterial breakpoints were those recommended by
the NCCLS [16]. For erythromycin, for which the NCCLS has
no breakpoints, ‘susceptible’ was defined as MIC  0.5 mg/L,
‘moderately susceptible’ as MIC 1–4 g/L, and ‘resistant’ as MIC
8 g/L.
RESULTS
H. influenzae
The susceptibility of clinical isolates of H. influenzae is shown in
Table 2. Susceptibility to ampicillin was seen in 90.1% of the
isolates collected in 1994 and in 93.1% of those collected in
1997. There was a good correlation between the clover-leaf test
and susceptibility to ampicillin. All isolates that were ampicillin
resistant (MIC 2) showed production of b-lactamase by the
clover-leaf test. In addition, two isolates of MIC of 1.0 and
1.5 mg/L were also positive for b-lactamase. Susceptibility to
doxycycline was 100% in 1994 and 99.8% in 1997. Suscept-
ibility to cephalothin decreased from 93.8% in 1994 to 90.6% in
1997.
S. pneumoniae
No decrease in susceptibility to penicillin was observed between
1994 and 1997 (Table 3). The susceptibilty was 98.9% in 1994
and 99.4% in 1997. Pneumococci were also highly susceptible
to cephalotin, erythromycin and doxycycline. To determine
any drift in the MIC of penicillin between 1993 and 1997, we
compared the MIC values for the pneumococcal population of
the two study periods (Table 4). As can be seen, no drift toward
higher MIC was observed.
Table 2 Susceptibility ofH. influenzae1993/1994^1997
1993^1994 1997
Antimicrobial Susceptibility (mg/L) No. % No. %
Ampicillin S (1) 145 90.1 430 93.3
I (2) 0 0 6 1.3
R (4) 16 8.9 25 5.4
Doxycycline S (2) 161 100 460 99.8
I (4) 0 0 1 0.2
R (8) 0 0 0 0
Cephalothin S (8) 151 93.8 418 90.6
I (10) 2 1.2 22 4.8
R (32) 8 5 21 4.6
Table 3 Susceptibility of S. pneumoniae1993/1994^1997
1993^1994 1997
Antimicrobial Susceptibility (mg/L) No. % No. %
Penicillin G S (0.06) 174 98.9 316 99.4
I (0.12^1) 0 0 2 0.6
R (2) 2 1.1 0 0
Erythromycin S (0.5) 172 97.7 316 99.4
I (1^4) 1 0.6 0 0
R (8) 3 1.7 2 0.6
Doxycycline S (4) 168 95.5 304 95.6
I (8) 1 0.6 8 2.5
R (16) 7 3.9 6 1.9
Cephalothin S (8) 176 100 318 100
I (16) 0 0 0 0
R (32) 0 0 0 0
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S. pyogenes
All isolates were susceptible to penicillin and cephalothin, and
98.3% (1994) and 98.4% (1997) were susceptible to erythro-
mycin (Table 5). The susceptibility to doxycycline decreased
from 98.3% in 1993 to 95.9% in 1997 (not significant).
Geographic distribution of resistant isolates
In 1993–1994, two penicillin-resistant isolates of pneumococci
were found (MIC¼ 3.0 mg/L). Both isolates were from a
4-year-old boy who had moved to Norway from the USA
6 months before the first specimen was collected. In the USA,
he had suffered repeated episodes of otitis media which were
treated with antibiotics. This particular penicillin-resistant
pneumococcal strain has not been isolated from the boy or
from any other persons since 1994. In 1997, there were five
strains of group A streptococci that were resistant to erythro-
mycin; these were all isolated from patients living in the County
of Rogaland, southern Norway. No pneumococcal isolates
were resistant to penicillin, but the two with decreased suscept-
ibility were both from the County of Rogaland. There were 25
(5.4%) of 461 isolates of H. influenzae resistant to ampicillin. Of
these, 15 were from Rogaland, six from Troms, three from
Østfold, and one from Telemark.
Drug consumption
The annual consumption of antibacterial agents in Norway
during the period 1992–1997 is shown in Table 6. The con-
sumption is measured as defined daily doses (DDD) per 1000
inhabitants per day and is classified into the international ATC
groups [17]. The total consumption of antibacterials (ATC
group J01) in Norway is low.
Table 4 S. pneumoniae: distributionof the isolates according toMIC (mg/L)
for penicillin during the two study periods
MIC (mg/L) 1993 (%) 1997 (%)
0.01 46 86.8
0.02 45.5 9.4
0.03 4.5 2.5
0.04 2.3 0
0.06 0 0.6
0.08 0 0.6
>0.08 1.7 0
Table 5 Susceptibility of S. pyogenes1993/1994^1997
1993^1994 1997
Antimicrobial Susceptibility (mg/L) No. % No. %
Penicillin G S (0.12) 181 100 513 100
I (0.25^2) 0 0 0 0
R (4) 0 0 0 0
Erythromycin S (0.5) 178 98.3 505 98.4
I (1^4) 0 0 3 0.6
R (8) 3 1.7 5 1
Doxycycline S (4) 178 98.3 492 95.9
I (8) 2 1.1 19 3.7
R (16) 1 0.6 2 0.4
Cephalothin S (8) 181 100 513 100
I (16) 0 0 0 0
R (32) 0 0 0 0
Table 6 Total consumption (DDD/1000 inhabitants/day) of antibacterial agents and of tetracyclines (J01A), penicillins (J01C), other b-lactam antibacterials
(J01D) andmacrolides and lincosamides (J01F) in all of Norway during the period1992^1997 [17]
1992 1993 1994 1995 1996 1997
Total (J01) 15.1 16.2 15.4 15.6 14.5 14.8
Tetracyclines (J01A) 4.44 4.78 4.32 4.14 3.66 3.55
Penicillins (J01C) 6.53 7.2 7.02 7.32 7.03 7.45
Other b-lactam antibacterials (J01D) 0.35 0.39 0.39 0.4 0.4 0.38
Macrolides and lincosamides (J01F) 1.44 1.6 1.46 1.58 1.51 1.58
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DISCUSSION
Bacterial antibiotic resistance among respiratory tract pathogens
has become an increasing problem in many countries during
recent years [1,6,10,11]. However, in some countries, among
them The Netherlands and Denmark, such resistance has not
yet become a significant medical problem [18,19]. The devel-
opment of antibacterial resistance is closely linked to consump-
tion of antibacterials [2,13–15]. In Iceland, a decline in the
prevalence of penicillin-resistant S. pneumoniae was observed
following a campaign aimed at reducing the prescription of
antibacterials [20]. In Norway, the consumption of antibacter-
ials is strictly regulated. The sale of antibacterials and other anti-
infective drugs is registered by The Norwegian Medicinal
Depot according to the international ATC classification of
drugs, and the total consumption of antibacterial drugs was
decreasing during the study period [17].
In Norway, no systematic study of bacterial resistance in
respiratory tract pathogens has been published. A study of 97
invasive isolates of S. pneumoniae from northern Norway
showed that only one isolate had decreased susceptibility to
penicillin [21]. Our study shows that bacterial resistance in
respiratory tract pathogens is scarce in Norway. In 1997, only
0.6% of pneumococcal isolates had decreased susceptibility to
penicillin. The susceptibility to doxycycline was 95.6% and that
to erythromycin was 99.4%. Like Icelanders, many Norwegians
travel to high endemic countries such as Spain on holidays.
However, no import of penicillin-resistant isolates of pneumo-
cocci to Norway has been reported. Most probably, however,
isolates of pneumococci with decreased susceptibility to peni-
cillin have been introduced to Norway. However, owing to the
low consumption of antibacterials in Norway, resistant isolates
will have no advantage over susceptible wild-type strains, and
their spread may be impaired.
The first b-lactamase-producing H. influenzae isolate in
Norway was reported in 1978 [22]. In a report on systemic
H. influenzae infections in the Scandinavian countries in 1990
[23], b-lactamase-producing H. influenzae was reported to be
rare in Norway. In a report from the National Institute of Public
Health in Oslo in 1991–1992, 10.5% of 124 blood and cere-
brospinal type b isolates of H. influenzae were shown to produce
b-lactamase [24]. In our study, no increase in the prevalence of
b-lactamase-producing respiratory isolates of H. influenzae was
seen. The prevalence of b-lactamase-producing H. influenzae
was only 6.9% in 1997, indicating that the prevalence of b-
lactamase-producing H. influenzae has not increased in the
1990s in Norway.
For group A streptococci, 98.4% of all isolates were suscep-
tible to erythromycin in 1997, and no increase was observed
between 1993 and 1997. In Finland, a high prevalence of
erythromycin resistance [12] was found, which was associated
with an increase in erythromycin consumption during the
preceding years. After reduction of the level of erythromycin
consumption, a decline in resistance was observed [25].
Most of the resistant bacteria in this study were isolated from
the County of Rogaland, which has only 29% of the study
population. Rogaland is the center for the international oil
industry in Norway, and has a large proportion of foreign
residents, as well as visitors. In 1998, the number of people
moving from foreign countries to Rogaland was 3906, com-
pared with 4400 for the rest of the counties covered by this study
[26]. However, the figures are too small to draw any conclu-
sions, and further studies are needed to determine if bacterial
resistance is more frequent in Rogaland than in other counties,
and, if so, what are the causes.
In conclusion, the prevalence of bacterial resistance remains
low in the surveyed population in Norway, but there seems to
be some geographic variation which requires further study.
Surveillance of bacterial resistance should be a continuous
process, so that immediate measures can be taken once bacterial
resistance appears.
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